IFN-γ-loaded dissolvable sugar microneedles for local intradermal delivery in cutaneous squamous cell carcinoma

Conference poster


Akmandor, T., Outram, S., Russo, C. and Loizidou, E. 2026. IFN-γ-loaded dissolvable sugar microneedles for local intradermal delivery in cutaneous squamous cell carcinoma. 22nd EADO Congress 2026. Prague, Czech Republic 23 - 25 Apr 2026 Elsevier. https://doi.org/10.1016/j.ejcskn.2026.101112
TypeConference poster
TitleIFN-γ-loaded dissolvable sugar microneedles for local intradermal delivery in cutaneous squamous cell carcinoma
AuthorsAkmandor, T., Outram, S., Russo, C. and Loizidou, E.
Abstract

Background: Cutaneous squamous cell carcinoma (cSCC) is a common non-melanoma skin cancer in which local immune modulation is clinically relevant. Interferon-gamma (IFN-γ) is a key immunomodulatory cytokine; however, its clinical application in skin disease is limited by challenges associated with controlled local delivery. Dissolvable microneedles offer a minimally invasive approach to bypass the stratum corneum and enable intradermal delivery of biologics. This study aimed to develop IFN-γ-loaded dissolvable sugar-based microneedles and evaluate their structural integrity and ability to achieve reproducible intradermal penetration in skin-relevant models.
Conceptual schematic of dissolving microneedle-mediated IFN-γ delivery. Microneedles penetrate the stratum corneum and dissolve following insertion, enabling local intradermal cytokine release within the cutaneous microenvironment. The approach is intended for localised cutaneous immunomodulation.

Methods: IFN-γ-loaded dissolving microneedles were fabricated using a sugar-based matrix via micro-moulding. Microneedle morphology and structural integrity were assessed using scanning electron microscopy (SEM). Intradermal penetration and delivery depth were evaluated using ex-vivo human skin and optical coherence tomography (OCT), with penetration depth assessed across multiple insertion sites.

Results: IFN-γ-loaded microneedles demonstrated uniform geometry and intact needle tips suitable for skin insertion. SEM confirmed consistent microneedle architecture, while OCT imaging demonstrated reproducible disruption of the stratum corneum and formation of intradermal microchannels extending into the viable epidermis and superficial dermis. Penetration depth was consistent across multiple microneedles within each array, supporting reliable intradermal delivery.
Structural integrity and skin penetration of dissolving microneedle arrays. (A) OCT imaging demonstrating consistent microneedle penetration into skin. (B) Schematic illustrating microneedle insertion across skin layers. (C) SEM showing microneedle geometry and tip sharpness. (D) SEM of skin surface confirming microneedle insertion sites.

Conclusions: This study demonstrates the feasibility of delivering IFN-γ-loaded dissolving microneedles into human skin using a minimally invasive approach. These findings support the potential of dissolvable microneedles as a local intradermal delivery platform for cytokine-based strategies in cutaneous squamous cell carcinoma, with future work required to evaluate pharmacodynamic and biological effects.

Sustainable Development Goals3 Good health and well-being
Middlesex University ThemeHealth & Wellbeing
Conference22nd EADO Congress 2026
Proceedings TitleEJC Skin Cancer
ISSN
Electronic2772-6118
PublisherElsevier
Publication dates
Online20 Apr 2026
Print2026
Publication process dates
Accepted2026
Deposited05 Oct 2026
Output statusPublished
Publisher's version
License
File Access Level
Open
Copyright Statement

User License: Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

Digital Object Identifier (DOI)https://doi.org/10.1016/j.ejcskn.2026.101112
Related Output
Has metadatahttps://publons.com/wos-op/publon/83296875/
Permalink -

https://repository.mdx.ac.uk/item/36v347

Download files


Publisher's version
PIIS2772611826003393.pdf
License: CC BY-NC-ND 4.0
File access level: Open

  • 2
    total views
  • 0
    total downloads
  • 2
    views this month
  • 0
    downloads this month

Export as

Related outputs

Imiquimod-loaded dissolving microneedles for enhanced dermal penetration in basal cell carcinoma immunotherapy: a feasibility and delivery study
Akmandor, T., Loizidou, E. and Russo, C. 2026. Imiquimod-loaded dissolving microneedles for enhanced dermal penetration in basal cell carcinoma immunotherapy: a feasibility and delivery study. 22nd EADO Congress 2026. Prague, Czech Republic 23 - 25 Apr 2026 Elsevier. https://doi.org/10.1016/j.ejcskn.2026.101113
Transdermal delivery of 5-fluorouracil via nanoparticle-infused microneedles: a pre-clinical study in superficial basal cell carcinoma
Sully, R., Akmandor, T., Garelick, H., Loizidou, E., Podoleanu, A. and Gubala, V. 2026. Transdermal delivery of 5-fluorouracil via nanoparticle-infused microneedles: a pre-clinical study in superficial basal cell carcinoma. 22nd EADO Congress 2026. Prague, Czech Republic 23 - 25 Apr 2026 Elsevier. https://doi.org/10.1016/j.ejcskn.2026.101124
Paclitaxel-loaded silica nanoparticle microneedle arrays enable sustained transdermal drug delivery for localised breast cancer therapy [Abstract]
Akmandor, T., Sully, R., Loizidou, E., Garelick, H., Podoleanu, A. and Gubala, V. 2026. Paclitaxel-loaded silica nanoparticle microneedle arrays enable sustained transdermal drug delivery for localised breast cancer therapy [Abstract]. ESMO Breast Cancer Congress 2026. Berlin, Germany 06 - 08 May 2026 Elsevier. https://doi.org/10.1016/j.esmoop.2026.107086
Molecular dynamics of PU.1 and annexin A1 in acute promyelocytic leukaemia cells following ATRA/ATO therapy
Akmandor, T. and Shi, Z. 2026. Molecular dynamics of PU.1 and annexin A1 in acute promyelocytic leukaemia cells following ATRA/ATO therapy. British Society for Haematology (BSH) 66th Annual Scientific Meeting 2026 . Liverpool, UK 18 - 21 Apr 2026 Wiley.
Transcriptional modulation of differentiation-associated markers during ATRA and ATO treatment in acute promyelocytic leukaemia cells
Akmandor, T., Tuduwage, D., Mire, M. and Shi, Z. 2026. Transcriptional modulation of differentiation-associated markers during ATRA and ATO treatment in acute promyelocytic leukaemia cells. British Society for Haematology (BSH) 66th Annual Scientific Meeting 2026 . Liverpool, UK 18 - 21 Apr 2026 Wiley.
Clinicopathological and molecular landscape of lynch-associated endometrial carcinoma undergoing surveillance: a retrospective single-centre cohort study
Akmandor, T., Scott, M., Thind, D., Ganeshram, N.P., Rosenthal, A.N. and Arora, R. 2026. Clinicopathological and molecular landscape of lynch-associated endometrial carcinoma undergoing surveillance: a retrospective single-centre cohort study. ESGO 2026 Congress. Copenhagen, Denmark 26 - 28 Feb 2026 Elsevier. https://doi.org/10.1016/j.ijgc.2025.103406
Histological assessment of inflammatory infiltrates in interstitial cystitis/bladder pain syndrome (IC/BPS): a comparative study of mast cell quantification techniques [Abstract]
Akmandor, T. and Freeman, A. 2025. Histological assessment of inflammatory infiltrates in interstitial cystitis/bladder pain syndrome (IC/BPS): a comparative study of mast cell quantification techniques [Abstract]. Medicine 2025: The Future of Medicine. RCP Annual Conference. London, UK 02 - 03 Jun 2025 Elsevier. https://doi.org/10.1016/j.clinme.2025.100405
316eP Imiquimod-loaded dissolvable microneedles: a novel pre-clinical immunotherapeutic approach for dermato-oncology
Akmandor, T., Russo, C., Loizidou, E., Leontiev, D. and Hyseni, A. 2025. 316eP Imiquimod-loaded dissolvable microneedles: a novel pre-clinical immunotherapeutic approach for dermato-oncology. ESMO Immuno-Oncology Congress 2025. London, UK 10 - 12 Dec 2025 Elsevier. https://doi.org/10.1016/j.iotech.2025.101515
315eP Pre-clinical feasibility and translational challenges of cytokine-loaded dissolvable microneedles for cutaneous immunotherapy
Akmandor, T., Outram, S., Russo, C. and Loizidou, E. 2025. 315eP Pre-clinical feasibility and translational challenges of cytokine-loaded dissolvable microneedles for cutaneous immunotherapy. ESMO Immuno-Oncology Congress 2025. London, UK 10 - 12 Dec 2025 Elsevier. https://doi.org/10.1016/j.iotech.2025.101514